Medpace Holdings, Inc. (NASDAQ:MEDP) Q3 2024 Earnings Conference Call October 22, 2024 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants David Windley - Jefferies Max Smock - William Blair Eric Coldwell - Baird Ann Hynes - Mizuho Dan Leonard - UBS Justin Bowers - DB Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Operator Good day, ladi ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock $0.01 par value MEDP NASDAQ Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT ...

Medpace Holdings, Inc. MEDP shares are trading lower on Tuesday after reporting its third-quarter financial results yesterday.Revenue rose 8.3% year-over-year to $533.3 million, missing the consensus of $540.99 million.On a constant currency basis, revenue increased by 8.1% in the quarter. As of September 30, backlog rose by 8.8% to $2.927 billion.Net new business awards totaled $533.7 million for the third quarter of 2024, resulting in a net book-to-bill ratio of 1.00x, compared to $611.5 million in the pr ...

| --- | --- | |-------|-------| | | | | | | | | | FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective ta ...

Medpace (MEDP) came out with quarterly earnings of $3.01 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.22 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 8.66%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $2.52 per share when it actually produced earnings of $2.75, delivering a surprise of 9.13%. Over ...

Exhibit 99.1 1 MEDPRCE Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com FOR IMMEDIATE RELEASE Media Contact: Michael Maley 513.579.9911 x12831 m.maley@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2024 Results • Revenue of $533.3 million in the third quarter of 2024 increased 8.3% from revenue of $492.5 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. • Net new business awards were $533.7 million in the third quarter of 2024, r ...

Medpace (MEDP) closed the most recent trading day at $343.05, moving +1.57% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.9%. Meanwhile, the Dow gained 0.81%, and the Nasdaq, a tech-heavy index, added 1.22%. The provider of outsourced clinical development services's shares have seen a decrease of 2.78% over the last month, surpassing the Medical sector's loss of 4.05% and falling behind the S&P 500's gain of 3.15%. Market participants will be close ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MEDP. Investigation Details On September 25, 2025, Jefferies downgraded Medpace, citing perceived weaknesses in the Com ...

In the latest market close, Medpace (MEDP) reached $354.65, with a -0.57% movement compared to the previous day. This change lagged the S&P 500's 0.03% gain on the day. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.2%. The provider of outsourced clinical development services's stock has dropped by 9.01% in the past month, falling short of the Medical sector's gain of 2.67% and the S&P 500's gain of 1.54%. The upcoming earnings release of Medpace will ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Medpace (MEDP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Medpace currently has an average brokerage recommendation (ABR ...